Diane Simeone, MD, NYU Langone Health, New York, NY, shares the progress to date of the observation BASECAMP-1 (NCT04981119) study investigating solid tumor analysis for HLA loss of heterozygosity (LOH) and apheresis for CAR T- cell manufacturing. Primary outcome measures are percentage of screened participants experiencing loss of heterozygosity (LOH) of HLA-A*02 identified by next generation sequencing and percentage of participants who can enroll in a Phase I/II CAR T-cell therapy study, EVEREST-1 (NCT05736731). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
